Clinical Trial

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

Study acronym: Teprotumumab
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2024 (before its estimated May 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
Trial Details
NCT Number NCT06275373
Lead Sponsor Walter Reed National Military Medical Center
Conditions Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
Enrollment 100 participants
Start Date 2021-05-12
Primary Completion 2026-05-12 (estimated)
Study Completion 2027-12-12 (estimated)
Updated on ClinicalTrials.gov 2024-02-23